COVID-19: Information for health plans and insurers
Quest Diagnostics is uniquely positioned to help health plans support their members, providers, and plan sponsors as they look for answers in the face of uncertainty. COVID-19 testing may offer the insight you need.
Health plans can rely on Quest Diagnostics today, just as you always have. We’re committed to working tirelessly alongside you to connect stakeholders and deliver the answers that will help us overcome this challenge together.
This page is updated frequently as new information becomes available and we continue increasing testing capacity to meet your needs.
Quest Diagnostics is receiving COVID-19 specimens and performing testing nationwide.
Drive-thru testing events at Walmart
Quest and Walmart have joined forces to host drive-thru testing events at select Walmart locations around the country. In the comfort of their own car, your eligible members can self-administer a COVID-19 diagnostic test under the supervision of a healthcare professional.
Drive-thru events are continually being added to the calendar. Your Quest representative will keep you updated on new event dates and locations.
Testing by appointment at patient service centers
Antibody testing to indicate COVID-19 immune response is now readily available at Quest’s patient service centers (PSCs). Your members can get tested at their local PSC by scheduling an appointment online or through the MyQuest™ app.
To help your members feel comfortable while seeking care at Quest, every PSC has strengthened its already-rigorous safety procedures and implemented new service enhancements.
Note that diagnostic testing for active COVID-19 infection cannot be performed at Quest PSCs. Members must visit their physician or other healthcare provider.
The Quest Analytics data feed system now offers dedicated daily COVID-19 test result data reports for health plan customers. Collecting test result data allows your organization to comply with reporting requirements and to understand how the COVID-19 pandemic is affecting your members.
As people shelter at home during the COVID-19 pandemic, alternative access to health services becomes increasingly critical for your providers and members.
Telehealth use was already on the rise, but the COVID-19 crisis means demand is now growing at a much faster pace. For two months, Quest will not charge a fee to our healthcare provider customers who launch telehealth capabilities with the Electronic Video Consulting (ELVI) tool from our longtime partner CompuGroup Medical (CGM).
This allows health plans and providers to accommodate new benefits set by the Centers for Medicare & Medicaid Services (CMS) that widen access to Medicare telehealth services.
Our InSure® ONE™ colorectal cancer screening kits allow members to collect a sample in the privacy of their own home. InSure ONE member reminders and provider notifications help drive improved member compliance and early detection. Plus, it helps health plans:
- Close gaps in care
- Manage costs
- Increase quality measures
- Comply efficiently with quality reporting requirements
Ask your Quest representative about our other at-home test kits available to your members.
Health plans rely on Quest HealthConnect™ to help your members better understand their benefits. And taking full advantage of benefits is more important than ever, especially for those members at greater risk for serious illness like COVID-19.
Quest HealthConnect goes beyond lab services to include wellness visits, risk assessments, and quality programs. Plus, we meet your members where they are—which is now more likely to be at their home. To improve care and communication, all results are delivered to the member, their doctor, and their health plan.
To increase testing capacity and make the ordering process more convenient for healthcare providers, Quest has implemented a one code ordering system for all types of molecular tests used to diagnose COVID-19 active infection.
Healthcare providers can now order COVID-19 molecular testing using a single code—39448. Ordering COVID-19 molecular testing with a single code allows Quest to more efficiently distribute testing to whichever platform offers the best capacity, either at the ordering site or across our network of laboratories. This helps improve turnaround time and result delivery for your members.
Quest will accept reimbursement of $100 for SARS-CoV-2 RNA (COVID-19), Nucleic-acid Amplification Test (test number: 39448).
Asymptomatic members may be given an IgG antibody serology test via blood draw. The IgG antibody serology test is one tool that may help identify people who may have been previously exposed to or overcome SARS-CoV-2. It may indicate prior infection which may be resolved, as well as potential protection against re-infection (“protective immunity”).*
Quest’s IgG antibody test may be especially useful for people without symptoms, including healthcare workers. Knowing IgG status helps give members and their healthcare providers insight for a more informed decision about returning to work and activity.
IgG antibody testing must be ordered by a physician using test code 39504. Members may make an appointment at a Quest patient service center for this test.
Quest will accept reimbursement of $55 for SARS-CoV-2 Serology (COVID-19) Antibody (IgG), Immunoassay (test number: 39504).
*While the role of antibodies in preventing COVID-19 disease has yet to be established, antibody testing for other respiratory illnesses (SARS, flu) provides insight into immunity to future diseases.
Quest Diagnostics further expands COVID-19 testing capacityRead Press Release
Quest has steadily increased COVID-19 testing capacity and turnaround times to meet the evolving needs of health plans, healthcare providers, and patients in our communities.
So far, we’ve processed more than 2.65 million active infection tests and 1.25 million immune response tests.
The antibody tests (sometimes known as the serology tests or IgG tests) are intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are for the detection of SARS-CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Individuals may have detectable virus present for several weeks following seroconversion. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, molecular testing for SARS-CoV-2 is necessary. The antibody test should not be used to diagnose acute SARS-CoV-2 infection. False positive results for the antibody test may occur due to cross-reactivity from pre-existing antibodies or other possible causes.
- The antibody tests and the molecular tests (together “All tests”) have not been FDA cleared or approved;
- All tests have been authorized by FDA under EUAs for use by authorized laboratories;
- The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
- The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and,
- All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.